| Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ... Jama 313 (19), 1924-1938, 2015 | 1616 | 2015 |
| Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia WJ Jansen, R Ossenkoppele, BM Tijms, AM Fagan, O Hansson, ... JAMA psychiatry 75 (1), 84-95, 2018 | 176 | 2018 |
| Age differences in neural correlates of route encoding and route recognition O Meulenbroek, KM Petersson, N Voermans, B Weber, G Fernández Neuroimage 22 (4), 1503-1514, 2004 | 109 | 2004 |
| Autobiographical memory retrieval in patients with Alzheimer's disease O Meulenbroek, M Rijpkema, RPC Kessels, MGMO Rikkert, G Fernández Neuroimage 53 (1), 331-340, 2010 | 88 | 2010 |
| Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease N Mattsson, C Groot, WJ Jansen, SM Landau, VL Villemagne, ... Alzheimer's & Dementia 14 (7), 913-924, 2018 | 86 | 2018 |
| Spatial working memory in aging and mild cognitive impairment: effects of task load and contextual cueing RPC Kessels, O Meulenbroek, G Fernández, MGM Olde Rikkert Aging, Neuropsychology, and Cognition 17 (5), 556-574, 2010 | 73 | 2010 |
| Altered brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3-dimensional 31P MR spectroscopic imaging study A Rijpma, M van der Graaf, O Meulenbroek, MGMO Rikkert, A Heerschap NeuroImage: Clinical 18, 254-261, 2018 | 71 | 2018 |
| Cognitive functioning, wellbeing and brain correlates in HIV-1 infected patients on long-term combination antiretroviral therapy MAM Janssen, O Meulenbroek, SCA Steens, B Goraj, M Bosch, ... Aids 29 (16), 2139-2148, 2015 | 61 | 2015 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease A Rijpma, O Meulenbroek, AMJ van Hees, JWC Sijben, B Vellas, ... Alzheimer's research & therapy 7, 1-12, 2015 | 47 | 2015 |
| Informed consent in dementia research. Legislation, theoretical concepts and how to assess capacity to consent O Meulenbroek, M Vernooij-Dassen, RPC Kessels, MJL Graff, ... European Geriatric Medicine 1 (1), 58-63, 2010 | 41 | 2010 |
| Age-effects on associative object–location memory O Meulenbroek, RPC Kessels, M De Rover, KM Petersson, MGMO Rikkert, ... Brain research 1315, 100-110, 2010 | 33 | 2010 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer’s disease: results from a randomized controlled trial A Rijpma, M van der Graaf, MM Lansbergen, O Meulenbroek, ... Alzheimer's research & therapy 9, 1-11, 2017 | 32 | 2017 |
| Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: a systematic review of randomized controlled trials A Rijpma, O Meulenbroek, MGMO Rikkert Ageing research reviews 16, 105-112, 2014 | 27 | 2014 |
| European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and … O Meulenbroek, S O'dwyer, D De Jong, G Van Spijker, S Kennelly, ... BMJ open 6 (7), e011584, 2016 | 20 | 2016 |
| Quantitative genetics validates previous genetic variants and identifies novel genetic players influencing Alzheimer’s disease cerebrospinal fluid biomarkers M Ramos de Matos, C Ferreira, SK Herukka, H Soininen, A Janeiro, ... Journal of Alzheimer’s Disease 66 (2), 639-652, 2018 | 15 | 2018 |
| How does additional diagnostic testing influence the initial diagnosis in patients with cognitive complaints in a memory clinic setting? AP Meijs, JAHR Claassen, MGM Olde Rikkert, BWM Schalk, ... Age and Ageing 44 (1), 72-77, 2015 | 15 | 2015 |
| Improved cerebrospinal fluid-based discrimination between Alzheimer’s disease patients and controls after correction for ventricular volumes LJC Van Waalwijk Van Doorn, JD Gispert, HB Kuiperij, JAHR Claassen, ... Journal of Alzheimer's Disease 56 (2), 543-555, 2017 | 11 | 2017 |
| Neural correlates of episodic memory in healthy aging and Alzheimer's disease. OV Meulenbroek [Sl]:[Sn], 2010 | 10 | 2010 |
| White matter hyperintensities are no major confounder for Alzheimer’s disease cerebrospinal fluid biomarkers LJC van Waalwijk van Doorn, M Ghafoorian, EMC van Leijsen, ... Journal of Alzheimer’s Disease 79 (1), 163-175, 2021 | 8 | 2021 |
| Comparing content of dementia care after diagnosis: memory clinics versus general practitioners EJ Meeuwsen, RJF Melis, O Meulenbroek, MGM Olde Rikkert Int J Geriatr Psychiatry 29 (4), 437-8, 2014 | 6 | 2014 |
Roy P.C. KesselsProfessor of Neuropsychology - Radboud University Nijmegen; Vincent van Gogh InstituteПотвърден имейл адрес: donders.ru.nl
